In recent years, HER2-low breast cancer has emerged as a distinct subtype, and the anti-HER2 antibody–drug conjugate trastuzumab deruxtecan (T-DXd) has become a promising treatment option. This evidence concerns the gene ERBB2 and breast cancer.